ep cad
stayin aliv -- surviv survivin peptid initi
outperform
initi coverag imv outperform rate cad pt tsx
base potenti two indic dpx-survivacovarian cancer dlbcl
believ imv approach combin precis oncolog immunotherapi
uniqu pursu new previous undrug survivin target could lead
major breakthrough oncolog appreci opportun combin
immunotherapi improv respons rate imv could potenti show
increment benefit orr ovarian/dlbcl trial success scenario could
unlock increas collabor financ larger partner acknowledg
binari natur imv clinic trial consid risk-reward profil support
dcf-deriv price target valuat cad
dpx platform imv dpx platform control releas deliveri system
accommod varieti applic peptid antibodi imv
immunotherapi use survivin-bas peptid licens merck kgaa
formul dpx dpx-survivac dpx-survivac leverag moa dpx
gener constant flow t-cell blood target survivin
express cancer cell
survivin survivin protein involv inhibit apoptosi regul
cell cycl survivin exhibit diverg function regul cell prolifer
cell death survivin absent normal termin differenti tissu
overexpress varieti human cancer express survivin
tumor correl inhibit apoptosi resist chemotherapi
aggress tumor
ovarian dpx-survivac studi open-label safeti
efficaci studi combo cyclophosphamid patient recurr
advanc platinum-sensitive/resist ovarian cancer accord literatur
survivin overexpress ovarian cancer patient trial studi
patient imv intend releas interim top-lin data
dlbcl dpx-survivac also non-random ist combo
cyclophosphamid pembro dlbcl patient studi expect enrol
patient approxim dlbcl patient estim overexpress
survivin test inclus criteria studi led sunnybrook institut
imv expect provid updat
valuat pt cad imv base dcf
valuat methodolog assum wacc residu growth rate
given imv financ clinic trial partial collabor
merck academ institut
year price histori imv inc
new class
cell activ
immunotherapi combin dpx
survivac clinic evalu
number cancer indic
analyst certif import disclosur see disclosur
outperform view imv base belief
share under-valued given reason risk-reward balanc
associ compani dpx platform survivin
antigen imv uniqu compani combin precis
oncolog immunotherapi compani major valu
driver dpx-survivac multipl clinic trial treat advanc
cancer patient given biomarker-driven clinic trial
assum averag probabl success
support opinion compani undervlalu
activ dpx-survivac combin ovarian cancer
demonstr trial
activ dpx-survivac combin pembro
dlbcl demonstr trial
continu collabor merck partner
updat result spirel trial dlbcl
top line result trial ovarian
top line result spirel trial dlbcl
top line result basket trial dpx-survivac
posit differenti dpx-survivac activ combin
pembro current trial
novel dpx-survivac combin cancer indic
greater expect advanc pipelin asset
acquisit signific premium
dpx-survivac activ combin trial and/or pembro
disappoint result
and/or clinic trial take longer expect and/
show statist signific
competit landscap ovarian and/or dlbcl limit dpx-
early-stag pipelin asset fail differenti offer strateg
advantag partnership collabor
price target base dcf valuat methodolog employ wacc termin
growth rate view appropri clinic stage pipelin estim dpx-survivac sale could reach
world-wide estim dpx-survicac reach ovarian cancer dlbcl risk-unadjust sale
employ risk adjust dpx-survivac ovarian cancer dlbcl indic
key downsid risk price target clinic develop regulatori risk dpx-survivac addit risk includ build
commerci infrastructur target indic higher anticip competit ovarian cancer dlbcl upsid risk includ
acquisit signific premium better expect clinic data dpx-survivac
note view imv stock trade specul appropri risk-toler investor
initi coverag imv corpor imv outperform rate cad
price target base larg current risk/reward profil two lead indic
dpx-survivacovarian cancer dlbcl diffus larg b-cell lymphoma price
target repres potenti upsid current trade level
believ combin immunotherapi futur improv respons rate
variou solid liquid tumor type dpx-survivac well posit challeng
statu quo standard care late-stag ovarian cancer dlbcl
possibl increment success dpx-survivac develop may lead
increas financ form collabor capit current merck potenti
big-pharma partner may drive market capit imv current
hand somewhat binari natur dpx-survivac clinic trial specif
combo dpx-survivac cyclophosphamid ovarian cancer expos
investor risk typic associ single-asset compani imv
think howev risk-reward profil imv support dcf-deriv price
target cad impli valuat cad usd
par averag valu early-stag immuno-oncolog compani
promis drug candid broad applic variou cancer type
price target cad imv base dcf valuat
methodolog assum wacc residu growth rate
view appropri given imv financ clinic trial partial
collabor agreement larg biopharma merck canadian/u
academ research institut plan launch pipelin asset
expect period
end imv cad cash market secur imv
current market capit around cad
includ imv early-stag candid valuat analysi re-
assess contribut imv valuat pipelin advanc
probabl success base biomedtracker-report averag success rate
biomarker-driven asset
dpx-survivac ovarian cancer indic believ
readout pdx-survivac orr result may lead subsequ
pivot trial ovarian cancer
dpx-survivac dlbcl believ dpx-survivac
combin pembrolizumab chanc achiev clinic meaning
respons rate recurrent/refractori dlbcl patient
also look compar compani early-stag cancer immunotherapi
platform five compar compani
averag trade market capit usd par target
market capit imv
exhibit market capit compar compani
key downsid risk price target includ clinic develop risk dpx-
survivac multipl clinic studi across number cancer indic
addit risk come build commerci infrastructur cancer indic post-
regulatori approv grant less expect sale due higher
anticip competit failur gain support physician commun us
payer imv may requir signific addit fund pre-launch commerci
oper form dilut equiti
key upsid risk price target includ acquisit signific premium
current share price better expect clinic data dpx-survivac
upcom imv catalyst includ updat result spirel studi dpx-survivac
pembrolizumab dlbcl decemb top line result
studi dpx-survivac top line result dpx-
survivac basket studi top line result studi
assum top line readout ovarian trial
primari import confirm singl target agent clinic efficaci dpx-survivac
exhibit catalyst calendar imv
histori stock price ownership
imv stock price ytd vs nbi
institut ownership ruffer llp largest sharehold
insid ninety-day averag volum share current short interest
float days-to-cov
factset oppenheim co note result view indic futur result
imv corpor clinical-stag biopharmaceut compani focus
immunotherapi treat oncolog diseas imv headquart dartmouth
scotia full time employe imv develop immunotherapi base
action control releas activ ingredi site inject forc
uptak deliveri activ ingredi immun cell lymph node enabl
program immun cell vivo aim gener new synthet
therapeut capabl dpx control releas moa leverag gener cell
therapi potenti transform treatment oncolog diseas
think imv two major compon drive valuat dpx platform
dpx-survivac combin platform survivac studi sever
indic includ two late-stag indicationsovarian cancer dlbcl
dpx proprietari control releas deliveri system sever advantag
synthet accommod hydrophil hydrophob compound amen
wide rang applic peptid antibodi small molecul
rna/dna imv first cancer immunotherapi use survivin-bas peptid licens
merck kgaa formul dpx dpx-survivac dpx-survivac leverag moa
dpx gener constant flow cell blood target survivin
express cancer cell compris five minim mhc class peptid activ
nave cell survivin
survivac survivin antigen previous known in-licens merck
kgaa survivin-bas cancer vaccin dpx-survivac compris five synthet
dpx-survivac ovarian cancer
dpx-survivac main clinic studi open-label studi evalu
safeti efficaci dpx-survivac intermitt low-dos cyclophosphamid
advanc recurr ovarian cancer
dpx-survivac dlbcl
anoth program dpx-survivac investigator-sponsor studi
evalu dpx-survivac target therapi combin pembrolizumab
pembro recurrent/refractori dlbcl
imv also on-going basket studi evalu dpx-survivac pembro five
cancer indic two pre-clin program bladder cancer melanoma
exclud studi valuat analysi due high correl later-stag
imv studi lower probabl clinic regulatori success
dpx platform imv-pat formul may provid specif way
present activ ingredi immun system dpx combin antigen
adjuv immun enhanc formul lipid nanoparticl suspend
directli oil freez dri
dpx may promot uptak extend exposur activ antigen adjuv
enhanc bodi immun system respons imv manag believ
abil dpx induc strong cellular immun respons make platform suitabl
cancer immunotherapi design target tumor cell
dpx may induc antigen-specif cellular respons requir effect tumor
control dpx platform potenti combin varieti antigen includ
recombin protein synthet peptid virus wide rang adjuv
dpx-base product report lyophil store dri format
provid benefit extend shelf life moreov dpx formul design
easi reconstitut administr
think platform provid competit differenti advantag
howev evalu platform combin therapeut agent imv pipelin
without alloc specif dollar valu platform alon
imv major drug candid dpx-base survivac protein target
overexpress survivin variou type cancer includ ovarian dlbcl
survivin survivac
survivin smallest member inhibitor apoptosi iap famili protein
involv inhibit apoptosi regul cell cycl survivin uniqu protein
exhibit diverg function regul cell prolifer cell death survivin
known express embryon develop absent normal
termin differenti tissu upregul varieti human cancer express
survivin tumor correl inhibit apoptosi resist
chemotherapi aggress tumor regard survivin may import
target cancer therapeut treat survivin inhibitor antigen
combin chemotherapi
iap famili protein found speci anim key protein famili
regul cell fate respons stress signal genom instabl therefor
dysregul iap function appar associ cancer develop
induct oncogenesi drug resist
investig mechan action iap cancer provid import lead
anti-cancer drug develop structur member iap contain approxim
amino acid iap known far survivin smallest iap protein singl
n-terminu bir domain c-terminu coil coil domain
exhibit survivin function inhibitor apoptosi
mite et al survivin regul mitosi apoptosi novel target
compar iap survivin exhibit restrict express adult tissu
crucial role regul cell divis apoptosi highli express
human cancer normal termin differenti adult tissu thu make
exhibit survivin overexpress variou cancer type
survivin encod gene consist exon intron cover
nucleotid chromosom form transcript vari function
five known addit splice variant
exhibit altern splice variant survivin encod gene
remain uncertain whether altern splice survivin cancer cell adapt
sustain prolifer avoid detect immun surveil associ
splice variant distinct patholog outcom may indic possibl role
variant tumor prolifer nevertheless contribut survivin variou splice
variant tumorigenesi immun evas respons treatment thoroughli
studi understood
regul cell divis recogn promin function survivin normal cell
show cell cycl depend synthesi express degrad survivin survivin
form integr compon chromosom passeng complex cpc ensur
proper segreg chromosom cytokinesi cell divis
variou checkpoint ensur nuclear divis attach mitot spindl
cytokinesi cpc hetero-tetramer complex local differ site
differ time mitosi serv regul key event cell divis
overexpress survivin inhibit intrins extrins pathway apoptosi
deplet survivin human cell induc defect apoptosi multipl defect
cell divis although mechan inhibit apoptosi survivin still
unknown direct indirect bind survivin initi effector caspas
suppos contribut inhibit apoptosi survivin
survivin also upregul vegf express promot endotheli cell prolifer
mechan still clear
survivin-induc vegf express contribut chemo-resist stimul
organ tubulin distinct fiber survivin particularli upregul tumor
vascular endotheli cell compar normal tissu thu confer drug resist
tumor vascular endotheli cell therefor target survivin tumor may promot
tumor cell death also sensit cell tumor vascular network
survivin uniqu role apoptosi cell divis survivin express
cytosol mitochondrion suppress extrins intrins pathway apoptosi
survivin express nucleu play import role regul cell divis
act import compon cpc
exhibit survivin role apoptosi cell divis
survivin target
survivin command central posit among iap regul cell
divis apoptosi howev normal differenti cell low
express survivin unclear whether low no-express survivin normal
cell correl function normal cell
anim model condit delet survivin thymu lead development
block thymocyt presenc immatur cell peripheri survivin also emerg
key regul clonal expans effector cell prolifer earli cell
progenitor activ matur cell survivin appear multi-funct protein
target survivin therapeut agent word immunotherapi target
survivin consid manipul host immun system produc
anti-tumor respons immun system manipul success use
immunotherapi believ becom
obviou better understand principl immunolog therapeut
approach treat cancer may becom divers synergist target human
recent year becom clear immunotherapi better therapeut option
compar chemotherapi radiotherapi specif tumor cell
immunotherapi elimin tumor cell initiating/ boost anti-tumor immun respons
revers inhibitori immun signal activ immunotherapi involv develop
target anti-tumor immun respons host use specif cancer antigen ex vivo
expans effector cell infus back patient passiv immunotherapi
cover transfer preform molecul therapeut antibodi antigen specif
cell elimin suppress tumor number monoclon antibodi
growth factor receptor antigen determin cancer cell
success translat therapeut usag variou cancer
circul tumor cell also express high level survivin may also respons
immun escap tumor cell chronic inflamm immun evas may work
synergist induc survivin upregul tumor cell nonetheless
increas interest develop immunotherapeut approach target survivin
promin role cancer develop abil induc effect
believ potenti applic use survivin inhibitor
immunotherapeut approach antigen given signific heterogen
human cancer translat develop survivin-bas inhibitor antigen may
show better result use combin tradit establish treatment
chemotherapi checkpoint inhibitor target therapi etc
survivac previous known initi develop merck kgaa
multi-epitop vaccin approach manipul immun system use combin
five survivin peptid montanid adjuv
dpx-survivac liposom formul survivin peptid develop
imv treat ovarian cancer dlbcl tumor type
exhibit dpx-survivac base immunotherapi impact cell repertoir treat tumor
dpx-survivac ovarian cancer
dpx-survivac current open-label safeti efficaci studi
combin individu recurr advanc platinum-sensit
resist ovarian cancer dpx-survivac/cpa arm trial
studi patient popul lower tumor burden
imv intend releas interim top line data soon threshold clinic respons
reach expect occur
exhibit studi design ovarian cancer
current treatment landscap ovarian cancer
current nccn guidelin recommend multipl target agent depend clinic
circumst biomark activ soc therapi includ bevacizumab rucaparib
pembrolizumab entrectinib larotrectinib other
howev respons rate late-lin therapi platinum-sensit patient remain low
preval platinum-resist ovarian cancer patient us current
estim market ovarian cancer current usd explain
limit efficaci select target agent ovarian cancer
dpx-survivac dlbcl
dpx-survivac evalu investigator-sponsor trial
combin pembrolizumab patient measur recurr dlbcl
studi led sunnybrook research institut imv expect provid updat
trial meet decemb
non-random open-label studi expect enrol evalu particip
canada novemb patient enrol across five differ
clinic site canada
research conduct investigator-sponsor studi test novel
immunotherapi combin patient whose dlbcl express survivin confirm
molecular test tumor antigen highli express dlbcl patient dpx
survivac assum stimul immun system produc cell respons
june imv provid updat data studi patient demonstr
clinic benefit includ four patient tumor regress combin
continu demonstr accept safeti profil
exhibit spirel studi design dlbcl
current treatment landscap dlbcl
lymphoma consid common form liquid tumor lymphoma
classifi two type hodgkin lymphoma hl non-hodgkin lymphoma nhl b-
cell lymphoma common sub-typ nhl dlbcl account newli
diagnos b-cell lymphoma preval patient us
accord nccn guidelin dlbcl current soc dlbcl domin
lenalidomid tisagenlecleucel axicabtagen ciloleucel other
rituximab initi approv dlbcl significantli extend overal
progress free surviv first second line therapi
exhibit rituximab efficaci result random studi dlbcl
howev eventu major patient progress approv soc regimen
car-t regimen approv fda yescarta axicabtagen ciloleucel
kymriah tisagenlecleucel estim patient potenti
cure car-t regimen
believ dpx-survivac combin pembrolizumab recurrent/refractori
dlbcl probabl clinic success given announc far dcr
orr high level survivin-specif cell blood patient
imv number early-stag trial dpx-survivac dpx-base drug
candid variou cancer indic valuat purpos includ
drug candid model appropri establish either potenti
sale probabl success indic drug candid time
view intellectu properti dpx-base composit includ dpx-
survivac well protect dpx-relat patent list base
imv sec file patent extend protect valuat purpos
model sale imv product declin rate termin growth post-
exhibit imv patent file last year
fred serv chief execut offic sinc april year
experi biopharmaceut industri serv sever manag
market commun join imv fred spent year medicago
serv recent vice presid busi develop strateg plan
particip secur cad non-dilut fund revenu
futur mileston licens agreement govern contract cad
acquisit deal mitsubishi pharma
fred also director cqdm biopharmaceut research consortium serv
second vice-chair vaccin industri committe biotech canada
prior medicago fred licens manag univers pari vii-
deni diderot franc hold bsc degre biolog master degre
busi manag univers anger franc
joann join imv oct year experi
biopharmaceut industri primarili early-stag oncolog drug develop
recent serv vice presid clinic develop execut medic
director biomedicin overse compani clinic develop effort
previous work vice presid clinic develop constel
pharmaceut earlier held variou clinic develop leadership role
syndevrx novarti freseniu biotech glycogenesi
joann hold univers connecticut school medicin
tuft univers school veterinari medicin biolog brandei
pierr chief offic imv sinc februari year
financi leadership role variou industri join imv vice
presid chief offic leddartech inc compani automot
industri experi life scienc sector includ serv chief
offic secretari medicago inc complet privat medicago
inc follow acquisit mitsubishi pharma enterpris valu cad
career senior financi offic particip develop
strateg plan financ merger acquisit
pierr also director osisko gold royalti ltd tsx nyse hold
bachelor degre busi administr licens account universit
laval qubec citi pierr member charter profession account
canada institut corpor director
stphan manag implement progress imv clinic program prior
join compani work year clinic research medicago
glaxosmithklin infecti diseas research center chul led
multifunct team sever therapeut area includ oncolog hiv vaccin
sepsi hematolog neurolog throughout career involv scientif
oper activ sever trial also led sever process
improv team overse time cost-effect deliveri clinic trial stephan
receiv honor universit laval master degre microbiolog
univers sherbrook
mariann overse preclin research activ clinic immunolog assess
cancer immunotherapi infecti diseas vaccin also serv adjunct
professor microbiolog immunolog dalhousi univers member
vaccin discoveri group canadian centr vaccinolog associ
member beatric hunter cancer research institut join compani
mariann conduct postdoctor train robart research institut
ottawa hospit research institut ohri focus research use
virus develop novel cancer treatment ohri work
jennerex biotherapeut sillajen develop pexa-vec human
clinic trial receiv bsc memori univers newfoundland
ph dalhousi univers
expect un-adjust sale imv reach cad ww driven primarili
two indic dpx-survivac ovarian cancer dlbcl assum probabl
success dpx-survivac ovarian cancer indic probabl success
dpx-survivac dlbcl indic assum launch dpx-survivac
assum usd monthli wac price dpx-survivac typic price
inject oncolog agent annual growth price in-lin long-term
project growth gross-to-net discount assum
exhibit forecast imv
imv except per share data fy risk-adjust survivac/cpa ovarian- survivac/cpa ovarian survivac/cpa pembro dlbcl- survivac/cpa pembro dlbcl revenu un-adjusted- goodscogs- gross profit- oper expensesresearch develop sell gener administr total oper expens cog sg gov oper incom non-oper incom expens interest interest expens accret govern busi develop investor pre-tax incom incom tax benefit expens tax ratenet incom basic share outstand share outstand ep ep oppenheim co estim compani data imv cn outperform
exhibit ovarian cancer forecast dpx-survivac
exhibit dlbcl forecast dpx-survivac
price target cad imv base dcf valuat
methodolog assum wacc residu growth rate
anticip launch dpx-survivac peak sale patent expir
imv sep cash balanc cad
forecast ww un-adjust sale dpx-survivac indic cad
mainli driven combin regiment pembrolizumab ovarian cancer
dlbcl assum probabl success dpx-survivac ovarian cancer
dlbcl
exhibit dcf valuat imv except share
probabl success
probabl success
good
research develop ifr
sell gener administr ifr
busi develop investor relat
stock price compani mention report
